Treatment of chemotherapy-induced peripheral neuropathy (CIPN) with topical menthol: A phase I study

Keyphrases

• Phase I Study 100%
• Menthol 100%
• Partial Responder 100%
• Chemotherapy-induced Peripheral Neuropathy 100%
• Non-responders 80%
• Hospital Anxiety 40%
• Depression Scale 40%
• Anxiety Scale 40%
• Long-term Chemotherapy 40%
• Cisplatin 20%
• Difficult-to-treat 20%
• Affected Area 20%
• Neuropathic Pain 20%
• Carboplatin 20%
• Patient-completed 20%
• Twice Daily 20%
• Long-term Disability 20%
• Dose-limiting Toxicity 20%
• Docetaxel 20%
• Novel Treatments 20%
• Bortezomib 20%
• Systemic Agents 20%
• Long-term Pain 20%
• Pain Severity 20%
• Dorsal Root Ganglion 20%
• Brief Pain Inventory 20%
• Oxaliplatin 20%
• Progressive Disease 20%
• Analgesic Effect 20%
• Catastrophizing 20%
• Pain Catastrophizing 20%
• Pain Interference 20%
• Transient Receptor Potential Melastatin 2 (TRPM2) 20%
• TRPM8 Gene 20%

Medicine and Dentistry

• Chemotherapy-Induced Peripheral Neuropathy 100%
• Side Effect 50%
• Hospital Anxiety and Depression Scale 50%
• Receptor 25%
• Cisplatin 25%
• Carboplatin 25%
• Docetaxel 25%
• Neuropathic Pain 25%
• Dorsal Root Ganglion 25%
• Brief Pain Inventory 25%
• Progressive Disease 25%
• Oxaliplatin 25%
• Pain Catastrophizing 25%
• Catastrophizing 25%
• TRPM8 25%
• Bortezomib 25%
• Analgesic Activity 25%
• Receptor Potential 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy-Induced Peripheral Neuropathy 100%
• Receptor 50%
• Side Effect 50%
• Catastrophizing 50%
• Disease 25%
• Cisplatin 25%
• Carboplatin 25%
• Analgesic Agent 25%
• Docetaxel 25%
• Neuropathic Pain 25%
• Oxaliplatin 25%
• Bortezomib 25%